Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma

Summary

It is a single arm, multicenter, phase 2 study to explore the efficacy and safety study of R2-MTX chemotherapy（Lenalidomide, Rituximab and Methotrexate）as first-line regimens in the treatment of newly diagnosed primary central nervous system lymphoma. Objective response rate is the primary endpoint.

Timeline

Start

2020-01-01

Primary completion

2022-10-15

Completion

2022-11-15

Publications

• Yuan X, Xie Y, Xu N, Liu H, Chen P, Zhao A, Liang Y, Qian W. Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma. Haematologica. 2024 Jun 1;109(6):2005-2009. doi: 10.3324/haematol.2023.284834. No abstract available.

Drugs

Indications